Amici G, Virga G, Da Rin G, Teodori T, Calzavara P, Bocci C
Nephrology and Dialysis Division, Regional Hospital S. Maria dei Battuti, Treviso, Italy.
Adv Perit Dial. 1995;11:78-82.
The aim of this study was to examine the possibility of increasing sodium and water removal with peritoneal dialysis. Ten patients aged 67.3 +/- 6.2 years, on continuous ambulatory peritoneal dialysis (CAPD) for 28.1 +/- 13.9 months, with no episodes of peritonitis for at least 2 months and clinically normohydrated, gave their informed consent to undergo two consecutive peritoneal equilibration tests (PETs) with dialysis solution at a sodium concentration of 126 mEq/L (low sodium) and 132 mEq/L (normal sodium), both with 2.5% glucose. Net ultrafiltration and sodium mass transfer were 319.4 +/- 178.5 and 443.2 +/- 234.4 mL (p = 0.0346) and 27.7 +/- 24.5 and 28.2 +/- 27.1 mEq (p = NS), respectively. There were no variations in natremia or the transport indices of the studied solutes or in the arterial pressure or heart rate. All patients showed drowsiness or torpor during the low sodium PET and one had cramps. The 126 mEq/L sodium dialysis solution showed no advantages compared to the more common solution, 132 mEq/L. However, further study is necessary to check the potentiality of solutions with different sodium and glucose compositions for both acute and chronic use.
本研究的目的是探讨通过腹膜透析增加钠和水清除的可能性。10名年龄为67.3±6.2岁的患者，接受持续非卧床腹膜透析（CAPD）28.1±13.9个月，至少2个月无腹膜炎发作且临床处于正常水合状态，他们均签署知情同意书，接受两次连续的腹膜平衡试验（PETs），分别使用钠浓度为126 mEq/L（低钠）和132 mEq/L（正常钠）的透析液，两种透析液均含2.5%葡萄糖。净超滤量和钠转运量分别为319.4±178.5和443.2±234.4 mL（p = 0.0346）以及27.7±24.5和28.2±27.1 mEq（p =无显著性差异）。血钠水平、所研究溶质的转运指标、动脉压或心率均无变化。所有患者在低钠PET期间均出现嗜睡或精神萎靡，1例出现痉挛。与更常用的132 mEq/L透析液相比，126 mEq/L钠透析液未显示出优势。然而，有必要进一步研究不同钠和葡萄糖组成的透析液在急性和慢性使用中的潜力。
